HOME >> BIOLOGY >> NEWS
Welch Award honors McConnell for insights into physical chemistry, cell membranes

ear magnetic resonance (NMR) data to the structure of molecules. He modified the equations governing NMR to include the effects of chemical reactions, and used the results to measure chemical kinetics, i.e., the speed at which reactions take place. He has also pioneered research on free radicals an extremely reactive type of chemical that occurs in chemical and biological settings; this ultimately led to the development of the McConnell Relation, which describes the distribution of electron spin in free radicals.

When Dr. McConnell moved to Stanford University in 1964, he began to use the methods of physical chemistry to study biological problems. There, he introduced a method called spin labels, in which electron and NMR spectra are used to study the structure and kinetics of proteins and lipids. His work showed how to measure the movement of molecules through and within membranes in the laboratory; this was later shown by many researchers to apply to living cell membranes. His research also showed how a protein present in the body combines with that of a foreign peptide on the cell membrane to enable the body to recognize a pathogenic invader.

Some of these discoveries are critical to understanding many properties of membranes, says Dr. McConnell, and a large portion of biology takes place in and on membranes, so understanding them is crucial.

Dr. McConnells recent work has focused on the behavior of cholesterol in membranes. Discoveries by his team concerning the properties of monomolecular films on the surface of water have shed light on cholesterol-phospholipid interactions that previously had puzzled scientists in several different fields of research.

Cholesterol forms special condensed complexes, says Dr. McConnell. By describing them mathematically, one can predict many of the properties that have been observed regarding cholesterol and phospholipid mixtures, which are major components of animal cell membranes. He believes th
'"/>

Contact: Melissa Quiroz
mquiroz@hillandknowlton.com
713-752-1916
The Welch Foundation
30-May-2002


Page: 1 2 3

Related biology news :

1. Harden McConnell named winner of 2002 Welch Award in Chemistry
2. Welch honors Kornberg for insights into DNA transcription
3. Welch Award honors 2 for unlocking natures secrets
4. Gladstone investigator Mike McCune wins prestigious NIH Directors Pioneer Award
5. UT Southwestern biochemist honored with NIH Directors Pioneer Award
6. Award winning researchers reveal potential new role for Glivec
7. UMaine anthropologist wins Solon T. Kimball Award
8. Secretary of Energy announces seven E.O. Lawrence Award Winners
9. Martin Saunders to receive the James Flack Norris Award
10. Berkeley Lab soil scientist Margaret Torn receives Presidential Early Career Award
11. NJIT professor receives Presidential Award for breakthrough research with adult stem cells

Post Your Comments:
(Date:12/10/2014)... 08, 2014 Research and Markets ... the "Biometrics Market in Japan 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 The integration of ... rural banking and upgradation of the driver,s license ... the market. Besides the aforementioned projects, biometrics is ...
(Date:12/5/2014)... 2014 Increased emphasis on product quality, ... testing and inspection technologies. The convergence of industries ... range of innovative test solutions. This trend is ... which is generally more inclined towards communication, media ... strategies of test equipment vendors will cater to ...
(Date:12/4/2014)... 3, 2014  Crossmatch™, a leading provider of ... DigitalPersona ® Pro Enterprise software and U.are.U ... throughout First Bank branch locations in ... and Virginia. First Bank, a progressive community ... North Carolina , selected the Crossmatch biometrics-based ...
Breaking Biology News(10 mins):Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3
(Date:12/19/2014)... YORK , Dec. 18, 2014 Relmada ... therapies for the treatment of chronic pain, announced the ... today. "This was a transformational year in ... promising future for our company," said Sergio Traversa ... year, we have executed on key financial, human resource ...
(Date:12/17/2014)... N.J. (PRWEB) December 17, 2014 ... (Euronext: IPN; ADR: IPSEY), today announced ... (referred to as Somatuline®) was approved by the ... treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adult ... advanced or metastatic disease to improve progression-free survival ...
(Date:12/17/2014)... 17, 2014 Audacity, a leading California-based ... member of the Huntsworth Health Group, is proud to ... team. In her role, Gonzales will serve as Senior ... incredibly honored to welcome a talent of Jamie’s caliber ... Gaëtan Fraikin. “She is a proven healthcare innovation leader ...
(Date:12/17/2014)... Mass. , Dec. 17, 2014   Synageva ... biopharmaceutical company developing therapeutic products for rare disorders, announced ... Conference being held in San Francisco, CA. ... President and Chief Executive Officer, will present on Monday, ... EST).  The presentation will be webcast live and may ...
Breaking Biology Technology:Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8Audacity Welcomes Healthcare Communications Expert Jamie Gonzales as Senior Vice President of Client Services 2
Cached News: